what drug is glp 1 Patients' Use GLP-1 Drugs for Weight Loss, Benefit Gains The next phase of the

The median follow-up duration was 1 year (IQR: 0.52 years), with key findings including a median weight loss of 11.7 kg and a median BMI at the most recent follow-up of 31.2 kg/m 2 , reflecting a median reduction of 3.7 kg/m 2

Abstract 552-P

35 In a retrospective, singlecentre study by Goncalves and Bell, 40 patients who were switched from liraglutide 1.8 mg (used for an average of 210 weeks) to OW semaglutide (average dose 0.76 mg) in clinical practice in the USA were followed for an average of 34 weeks

In agreement with the profound anti-inflammatory effects of GLP-1RAs, a recent study demonstrated a protective effect of these medications against the development of non-exudative AMD compared with other diabetes and lipid-lowering medications

Updated May 2025